nach oben

Schmerz Nachrichten

Erschienen in:

01.09.2021 | DFP

Praktische Aspekte der transdermalen und topischen Schmerztherapie

verfasst von: Dr. Stefan Neuwersch-Sommeregger, MSc, Dr Markus Köstenberger, Prim. Univ.-Prof. Dr. Rudolf Likar, MSc

Erschienen in: Schmerz Nachrichten | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

In diesem DFP-Literaturstudium werden die beiden unterschiedlichen Therapiekonzepte „transdermale“ und „topische“ Schmerztherapie beschrieben, deren Indikationen, Wirkungen und potenziellen Nebenwirkungen diskutiert und Tipps für deren Anwendung in der klinischen Praxis gegeben.

Vorheriger Artikel Botulinum-Neurotoxin in der Schmerztherapie — Pharmakologische Grundlagen

Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008; 26(11):1261–1268CrossRef

Guy RH. Transdermal drug delivery. Handb Exp Pharmacol 2010; 197:399–410CrossRef

Stanos S. Topical Analgesics. Phys Med Rehabil Clin N Am 2020; 31(2):233–244CrossRef

Watkinson AC, Kearney MC, Quinn HL, Courtenay AJ, Donnelly RF. Future of the transdermal drug delivery market—have we barely touched the surface? Expert Opin Drug Deliv 2016; 13(74):523–532CrossRef

Likar R. Praxis der transdermalen Schmerztherapie. Uni-Med Science, Bremen 2004

Smith E, Surber C. The Absolute Fundamentals of Transdermal Permeation. In: Gabard B, Elsner P, Surber P, Treffel P (Hrsg). Dermatopharmacology of Topical Preparations. Springer, Berlin/Heidelberg 2000; 23–36CrossRef

Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004; 3(2): 115–124CrossRef

Karande P, Jain A, Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol 2004; 22(2):192–197CrossRef

Stanley TH. The history and development of the fentanyl series. J Pain Symptom Manage 1992; 7(3):3–7CrossRef

10.

Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53(1):109–138CrossRef

11.

Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989; 70(6):928–934CrossRef

12.

Radbruch L, Sabatowski R, Petzke F, Brunsch-Radbruch A, Grond S, Lehmann KA. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med 2001; 15(4):309–321CrossRef

13.

Radbruch L. Ambulante Einstellung der transdermalen Tumorschmerztherapie mit Fentanyl. Deutsches Ärzteblatt 1999; 96:2026–2028

14.

Stanos SP. Topical agents for the management of musculoskeletal pain. J Pain Symptom Manage 2007; 33(3):342–355CrossRef

15.

Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12(12):1063–1073CrossRef

16.

Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000; 60(3):555–574CrossRef

17.

Tegeder I, Muth-Selbach U, Lotsch J, Rusing G, Oelkers R, Brune K et al. Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clin Pharmacol Ther 1999; 65(4):357–368CrossRef

18.

Rolf C, Engstrom B, Beauchard C, Jacobs LD, Le Liboux A. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford) 1999; 38(6):564–567CrossRef

19.

Nastiti C, Ponto T, Abd E, Grice JE, Benson HAE, Roberts MS. Topical Nano and Microemulsions for Skin Delivery. Pharmaceutics 2017; 9(4)

20.

Matthieu L, Meuleman L, Van Hecke E, Blondeel A, Dezfoulian B, Constandt L et al. Contact and photocontact allergy to ketoprofen. The Belgian experience. Contact Dermatitis 2004; 50(4):238–241CrossRef

21.

De Benedittis G, Lorenzetti A. Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: a double-blind crossover placebo-controlled study. Pain 1996; 65(1):45–51CrossRef

22.

Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010; 9(8):807–819CrossRef

23.

Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?. Clin J Pain 2008; 246(2):142–154CrossRef

24.

EMA: Qutenza. https://www.ema.europa.eu/en/documents/overview/qutenza-epar-summary-public_de.pdf (2015). Accessed 26. 7. 2021

25.

Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin 2013; 29(6):673–683CrossRef

26.

Maihofner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study. Eur J Pain 2014; 18(5):671–679CrossRef

27.

EMA: Qutenza Fachinformation. https://www.ema.europa.eu/en/documents/product-information/qutenza-epar-product-information_de.pdf (2019). Accessed 26. 7. 2021

28.

Likar R. Update in der Tumorschmerztherapie. http://paincourse.com/upload/pdf-a-13/tumorschmerztherapie-2013-likar.pdf (2013). Accessed 26. 7. 2021

Titel: Praktische Aspekte der transdermalen und topischen Schmerztherapie
verfasst von: Dr. Stefan Neuwersch-Sommeregger, MSc
Dr Markus Köstenberger
Prim. Univ.-Prof. Dr. Rudolf Likar, MSc
Publikationsdatum: 01.09.2021
Verlag: Springer Vienna
Erschienen in: Schmerz Nachrichten / Ausgabe 3/2021
Print ISSN: 2076-7625
Elektronische ISSN: 2731-3999
DOI: https://doi.org/10.1007/s44180-021-0014-y

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

President’s Corner

Neuraltherapie — Definition, Wirkmechanismen und Wirksamkeit

Editorial

Diskussion zur “Opioid-Krise“ in den USA

Praehabilitation bei onkologischen Erkrankungen

Clinical Efficacy of Platelet-Rich Plasma Injection and Its Association with Growth Factors in the Treatment of Mild to Moderate Knee Osteoarthritis. A Randomized Double-Blind Controlled Clinical Trial as Compared with Hyaluronic Acid.